viewAllergy Therapeutics PLC

Allergy Therapeutics raises £10.6mln to fund expansion of late-stage PQ Grass study

As well as funding the late-stage PQ Grass trial, the cash will also be used to part-fund the phase II study of Acarovac, the company’s dust mite allergy treatment

girl with hay fever
The phase III PQ Grass trial is pencilled in the diary for the second half of 2019

Allergy Therapeutics plc (LON:AGY) has raised £10.6mln to fund the expansion of the phase III clinical trial of its grass pollen-induced hay fever immunotherapy.

The AIM-quoted firm placed 40mln new shares at 26.5p each – slightly below yesterday’s closing price of 28p.

READ: AGY full-year revenues to rise despite weak pollen season

“Allergy Therapeutics is poised for a transformational period of growth both with our marketed products and our R&D pipeline,” said chief executive Manuel Llobet.

“With this successful placing and subscription, we will expand our planned phase III PQ Grass trial, scheduled to start in H2 2019, including a project to analyse pollen trends in the US to maximise the exposure of patients to grass pollen.

“We will also support the Acarovac phase II trial and, looking further out, further progress our diversified pipeline of patient-friendly, convenient to use products including Polyvac Peanut.”

Earlier this year, Allergy hailed the “extremely positive results” from the phase II trial of PQ Grass, with those taking the drug showing “a highly statistically significant” reduction in symptoms compared to patients in the placebo arm of the study.

READ: AGY readies PQ Grass for phase III trial

Allergy already has a treatment for grass pollen-induced allergic rhinitis – a fancy term for hay fever. But this new formulation is an injection which includes an adjuvant to help boost the body’s immune response.

One of the key target markets for PQ Grass is the US, where it would be the first immunotherapy injection to be registered and where peak grass vaccine sales could be US$300-$400mln a year.

As well as funding the late-stage PQ Grass trial, the cash will also be used to part-fund the phase II study of Acarovac, the company’s dust mite allergy treatment.

Allergy share dipped 2.5% to 27p on Thursday morning.

--Updates for completion of placing, share price--

Quick facts: Allergy Therapeutics PLC

Price: 16.25 GBX

Market: AIM
Market Cap: £103.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...


Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read